Switching to long-acting anti-retroviral therapy with no baseline resistance data: is there value in proviral DNA sequencing? A single-centre pilot study
Switching to long-acting anti-retroviral therapy with no baseline resistance data: is there value in proviral DNA sequencing? A single-centre pilot study
DannenbergCMatthewsHHüfnerA, et al.Long-term real-world use of cabotegravir/rilpivirine: adherence and virological efficacy over a 44-Month observation period. Infect Dis Ther2025; 14(8): 1775–1797. https://doi.org/10.1007/s40121-025-01178-3
2.
WatersLWinstonAReevesI, et al.BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022. HIV Med2022; 23(Suppl 5): 3–115. https://doi.org/10.1111/hiv.13446
3.
LiuTFShaferRW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis2006; 42(11): 1608–1618.
4.
CampagnaRNonneCAntonelliG, et al.Archived HIV-1 drug resistance mutations: role of proviral HIV-1 DNA genotype for the management of virological responder people living with HIV. Viruses2024; 16(11): 1697. https://doi.org/10.3390/v16111697
5.
GilbertMFerréVMGuilbaudR, et al.How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?J Antimicrob Chemother2025; 29: dkaf353. https://doi.org/10.1093/jac/dkaf353
